ERBB2 and non-small cell lung carcinoma: The efficacy of dual inhibition of EGFR and HER-2 has been documented in EGFR wild-type NSCLC cell lines combining gefitinib or erlotinib with trastuzumab or pertuzumab [14, 31, 32], and in EGFR T790M mutant cell lines combining anti-EGFR, anti HER-2 and anti HER-3 antibodies [33].